inclusion criteria: 1. aged ≥ 20 and ≤ 70 years 2. sars-cov-2 infection confirmed by real-time rt-pcr ≤ 4 days before randomization. 3. symptoms of mild to moderate illness with covid-19 at screening. at least one key covid-19 symptom should have a score of 2 or higher using the scoring system in the diary card, with the exception of fever, sense of smell, and sense of taste where participants may be enrolled with a score of 1 or higher. 4. have a negative serum pregnancy test at screening (for female participants of childbearing potential). a female participant who is of childbearing potential agrees to remain abstinent or use (or have their partner use) two acceptable methods of birth control within the projected duration of the study. acceptable methods of birth control are: intrauterine device, hormonal contraception, diaphragm with spermicide, contraceptive sponge, condom, vasectomy, as per local regulations or guidelines. 5. alanine aminotransferase (alt) or aspartate aminotransferase (ast) ≤ 2.5-fold of upper limit of normal (uln) and total bilirubin ≤ 1.5-fold of uln. 6. creatinine clearance ≥ 50 ml/min. 7. a female participant who is not of childbearing potential is eligible without requiring the use of contraception. a female participant who is not of childbearing potential is defined as one who has either: 1. reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels in the postmenopausal range as determined by the laboratory, or 12 months of spontaneous amenorrhea), or 2. at least six weeks postsurgical documented total hysterectomy and/or bilateral salpingo-oophorectomy, or 3. bilateral tubal ligation 8. participant or the participant's legal representative understands the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written informed consent. 9. provide written informed consent for the study and willing to adhere to dose regimen and visit schedules.

inclusion criteria: 1. aged ≥ 20 and ≤ 70 years 2. sars-cov-2 infection confirmed by real-time rt-pcr ≤ 4 days before randomization. 3. symptoms of mild to moderate illness with covid-19 at screening. at least one key covid-19 symptom should have a score of 2 or higher using the scoring system in the diary card, with the exception of fever, sense of smell, and sense of taste where participants may be enrolled with a score of 1 or higher. 4. have a negative serum pregnancy test at screening (for female participants of childbearing potential). a female participant who is of childbearing potential agrees to remain abstinent or use (or have their partner use) two acceptable methods of birth control within the projected duration of the study. acceptable methods of birth control are: intrauterine device, hormonal contraception, diaphragm with spermicide, contraceptive sponge, condom, vasectomy, as per local regulations or guidelines. 5. alanine aminotransferase (alt) or aspartate aminotransferase (ast) ≤ 2.5-fold of upper limit of normal (uln) and total bilirubin ≤ 1.5-fold of uln. 6. creatinine clearance ≥ 50 ml/min. 7. a female participant who is not of childbearing potential is eligible without requiring the use of contraception. a female participant who is not of childbearing potential is defined as one who has either: 1. reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels in the postmenopausal range as determined by the laboratory, or 12 months of spontaneous amenorrhea), or 2. at least six weeks postsurgical documented total hysterectomy and/or bilateral salpingo-oophorectomy, or 3. bilateral tubal ligation 8. participant or the participant's legal representative understands the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written informed consent. 9. provide written informed consent for the study and willing to adhere to dose regimen and visit schedules.

inclusion criteria: aged ≥ 20 and ≤ 70 years sars-cov-2 infection confirmed by real-time rt-pcr ≤ 4 days before randomization. symptoms of mild to moderate illness with covid-19 at screening. at least one key covid-19 symptom should have a score of 2 or higher using the scoring system in the diary card, with the exception of fever, sense of smell, and sense of taste where participants may be enrolled with a score of 1 or higher. have a negative serum pregnancy test at screening (for female participants of childbearing potential). a female participant who is of childbearing potential agrees to remain abstinent or use (or have their partner use) two acceptable methods of birth control within the projected duration of the study. acceptable methods of birth control are: intrauterine device, hormonal contraception, diaphragm with spermicide, contraceptive sponge, condom, vasectomy, as per local regulations or guidelines. alanine aminotransferase (alt) or aspartate aminotransferase (ast) ≤ 2.5-fold of upper limit of normal (uln) and total bilirubin ≤ 1.5-fold of uln. creatinine clearance ≥ 50 ml/min. a female participant who is not of childbearing potential is eligible without requiring the use of contraception. a female participant who is not of childbearing potential is defined as one who has either: reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels in the postmenopausal range as determined by the laboratory, or 12 months of spontaneous amenorrhea), or at least six weeks postsurgical documented total hysterectomy and/or bilateral salpingo-oophorectomy, or bilateral tubal ligation participant or the participant's legal representative understands the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written informed consent. provide written informed consent for the study and willing to adhere to dose regimen and visit schedules.

inclusion criteria: aged ≥ 20 and ≤ 70 years sars-cov-2 infection confirmed by real-time rt-pcr ≤ 4 days before randomization. symptoms of mild to moderate illness with covid-19 at screening. at least one key covid-19 symptom should have a score of 2 or higher using the scoring system in the diary card, with the exception of fever, sense of smell, and sense of taste where participants may be enrolled with a score of 1 or higher. have a negative serum pregnancy test at screening (for female participants of childbearing potential). a female participant who is of childbearing potential agrees to remain abstinent or use (or have their partner use) two acceptable methods of birth control within the projected duration of the study. acceptable methods of birth control are: intrauterine device, hormonal contraception, diaphragm with spermicide, contraceptive sponge, condom, vasectomy, as per local regulations or guidelines. alanine aminotransferase (alt) or aspartate aminotransferase (ast) ≤ 2.5-fold of upper limit of normal (uln) and total bilirubin ≤ 1.5-fold of uln. creatinine clearance ≥ 50 ml/min. a female participant who is not of childbearing potential is eligible without requiring the use of contraception. a female participant who is not of childbearing potential is defined as one who has either: reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels in the postmenopausal range as determined by the laboratory, or 12 months of spontaneous amenorrhea), or at least six weeks postsurgical documented total hysterectomy and/or bilateral salpingo-oophorectomy, or bilateral tubal ligation participant or the participant's legal representative understands the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written informed consent. provide written informed consent for the study and willing to adhere to dose regimen and visit schedules.

inclusion criteria: aged ≥ 20 and ≤ 70 years sars-cov-2 infection confirmed by real-time rt-pcr ≤ 4 days before randomization. symptoms of mild illness with covid-19 at screening. at least one key covid-19 symptom should have a score of 2 or higher using the scoring system in the diary card, with the exception of fever, sense of smell, and sense of taste where participants may be enrolled with a score of 1 or higher. have a negative serum pregnancy test at screening (for female participants of childbearing potential). a female participant who is of childbearing potential agrees to remain abstinent or use (or have their partner use) two acceptable methods of birth control within the projected duration of the study. acceptable methods of birth control are: intrauterine device, hormonal contraception, diaphragm with spermicide, contraceptive sponge, condom, vasectomy, as per local regulations or guidelines. alanine aminotransferase (alt) or aspartate aminotransferase (ast) ≤ 2.5-fold of upper limit of normal (uln) and total bilirubin ≤ 1.5-fold of uln. creatinine clearance ≥ 50 ml/min. a female participant who is not of childbearing potential is eligible without requiring the use of contraception. a female participant who is not of childbearing potential is defined as one who has either: reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels in the postmenopausal range as determined by the laboratory, or 12 months of spontaneous amenorrhea), or at least six weeks postsurgical documented total hysterectomy and/or bilateral salpingo-oophorectomy, or bilateral tubal ligation participant or the participant's legal representative understands the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written informed consent. provide written informed consent for the study and willing to adhere to dose regimen and visit schedules.

inclusion criteria: aged ≥ 20 and ≤ 70 years sars-cov-2 infection confirmed by real-time rt-pcr ≤ 4 days before randomization. symptoms of mild illness with covid-19 at screening. at least one key covid-19 symptom should have a score of 2 or higher using the scoring system in the diary card, with the exception of fever, sense of smell, and sense of taste where participants may be enrolled with a score of 1 or higher. have a negative serum pregnancy test at screening (for female participants of childbearing potential). a female participant who is of childbearing potential agrees to remain abstinent or use (or have their partner use) two acceptable methods of birth control within the projected duration of the study. acceptable methods of birth control are: intrauterine device, hormonal contraception, diaphragm with spermicide, contraceptive sponge, condom, vasectomy, as per local regulations or guidelines. alanine aminotransferase (alt) or aspartate aminotransferase (ast) ≤ 2.5-fold of upper limit of normal (uln) and total bilirubin ≤ 1.5-fold of uln. creatinine clearance ≥ 50 ml/min. a female participant who is not of childbearing potential is eligible without requiring the use of contraception. a female participant who is not of childbearing potential is defined as one who has either: reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels in the postmenopausal range as determined by the laboratory, or 12 months of spontaneous amenorrhea), or at least six weeks postsurgical documented total hysterectomy and/or bilateral salpingo-oophorectomy, or bilateral tubal ligation participant or the participant's legal representative understands the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written informed consent. provide written informed consent for the study and willing to adhere to dose regimen and visit schedules.

inclusion criteria: 2. sars-cov-2 infection confirmed by real-time rt-pcr ≤ 4 days before randomization. 3. symptoms of mild illness with covid-19 at screening. at least one key covid-19 symptom should have a score of 2 or higher using the scoring system in the diary card, with the exception of fever, sense of smell, and sense of taste where participants may be enrolled with a score of 1 or higher. 4. have a negative serum pregnancy test at screening (for female participants of childbearing potential). a female participant who is of childbearing potential agrees to remain abstinent or use (or have their partner use) two acceptable methods of birth control within the projected duration of the study. acceptable methods of birth control are: intrauterine device, hormonal contraception, diaphragm with spermicide, contraceptive sponge, condom, vasectomy, as per local regulations or guidelines. 5. alanine aminotransferase (alt) or aspartate aminotransferase (ast) ≤ 2.5-fold of upper limit of normal (uln) and total bilirubin ≤ 1.5-fold of uln. 6. creatinine clearance ≥ 50 ml/min. 7. a female participant who is not of childbearing potential is eligible without requiring the use of contraception. a female participant who is not of childbearing potential is defined as one who has either: reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels in the postmenopausal range as determined by the laboratory, or 12 months of spontaneous amenorrhea), or at least six weeks postsurgical documented total hysterectomy and/or bilateral salpingo-oophorectomy, or bilateral tubal ligation 8. participant or the participant's legal representative understands the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written informed consent. 9. provide written informed consent for the study and willing to adhere to dose regimen and visit schedules.

inclusion criteria: 2. sars-cov-2 infection confirmed by real-time rt-pcr ≤ 4 days before randomization. 3. symptoms of mild illness with covid-19 at screening. at least one key covid-19 symptom should have a score of 2 or higher using the scoring system in the diary card, with the exception of fever, sense of smell, and sense of taste where participants may be enrolled with a score of 1 or higher. 4. have a negative serum pregnancy test at screening (for female participants of childbearing potential). a female participant who is of childbearing potential agrees to remain abstinent or use (or have their partner use) two acceptable methods of birth control within the projected duration of the study. acceptable methods of birth control are: intrauterine device, hormonal contraception, diaphragm with spermicide, contraceptive sponge, condom, vasectomy, as per local regulations or guidelines. 5. alanine aminotransferase (alt) or aspartate aminotransferase (ast) ≤ 2.5-fold of upper limit of normal (uln) and total bilirubin ≤ 1.5-fold of uln. 6. creatinine clearance ≥ 50 ml/min. 7. a female participant who is not of childbearing potential is eligible without requiring the use of contraception. a female participant who is not of childbearing potential is defined as one who has either: reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels in the postmenopausal range as determined by the laboratory, or 12 months of spontaneous amenorrhea), or at least six weeks postsurgical documented total hysterectomy and/or bilateral salpingo-oophorectomy, or bilateral tubal ligation 8. participant or the participant's legal representative understands the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written informed consent. 9. provide written informed consent for the study and willing to adhere to dose regimen and visit schedules.

inclusion criteria: 2. sars-cov-2 infection confirmed by real-time rt-pcr ≤ 4 days before randomization. 3. symptoms of mild illness with covid-19 at screening. at least one key covid-19 symptom should have a score of 2 or higher using the scoring system in the diary card, with the exception of fever, sense of smell, and sense of taste where participants may be enrolled with a score of 1 or higher. 4. have a negative serum pregnancy test at screening (for female participants of childbearing potential). a female participant who is of childbearing potential agrees to remain abstinent or use (or have their partner use) two acceptable methods of birth control within the projected duration of the study. acceptable methods of birth control are: intrauterine device, hormonal contraception, diaphragm with spermicide, contraceptive sponge, condom, vasectomy, as per local regulations or guidelines. 5. alanine aminotransferase (alt) or aspartate aminotransferase (ast) ≤ 2.5-fold of upper limit of normal (uln) and total bilirubin ≤ 1.5-fold of uln. 6. creatinine clearance ≥ 50 ml/min. 7. a female participant who is not of childbearing potential is eligible without requiring the use of contraception. a female participant who is not of childbearing potential is defined as one who has either: 1. reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels in the postmenopausal range as determined by the laboratory, or 12 months of spontaneous amenorrhea), or 2. at least six weeks postsurgical documented total hysterectomy and/or bilateral salpingo-oophorectomy, or 3. bilateral tubal ligation 8. participant or the participant's legal representative understands the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written informed consent. 9. provide written informed consent for the study and willing to adhere to dose regimen and visit schedules.

inclusion criteria: 2. sars-cov-2 infection confirmed by real-time rt-pcr ≤ 4 days before randomization. 3. symptoms of mild illness with covid-19 at screening. at least one key covid-19 symptom should have a score of 2 or higher using the scoring system in the diary card, with the exception of fever, sense of smell, and sense of taste where participants may be enrolled with a score of 1 or higher. 4. have a negative serum pregnancy test at screening (for female participants of childbearing potential). a female participant who is of childbearing potential agrees to remain abstinent or use (or have their partner use) two acceptable methods of birth control within the projected duration of the study. acceptable methods of birth control are: intrauterine device, hormonal contraception, diaphragm with spermicide, contraceptive sponge, condom, vasectomy, as per local regulations or guidelines. 5. alanine aminotransferase (alt) or aspartate aminotransferase (ast) ≤ 2.5-fold of upper limit of normal (uln) and total bilirubin ≤ 1.5-fold of uln. 6. creatinine clearance ≥ 50 ml/min. 7. a female participant who is not of childbearing potential is eligible without requiring the use of contraception. a female participant who is not of childbearing potential is defined as one who has either: 1. reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels in the postmenopausal range as determined by the laboratory, or 12 months of spontaneous amenorrhea), or 2. at least six weeks postsurgical documented total hysterectomy and/or bilateral salpingo-oophorectomy, or 3. bilateral tubal ligation 8. participant or the participant's legal representative understands the study procedures, alternative treatments available, risks involved with the study, and voluntarily agrees to participate by giving written informed consent. 9. provide written informed consent for the study and willing to adhere to dose regimen and visit schedules.